Clinical Cancer Research: 5 (11)

Editorials

Editorials

p53 Prognostication: Paradigm or Paradox?

Jack A. Roth

Clin Cancer Res November 1 1999 5 (11) 3345-;
Editorials

Drug Resistance: Still on the Learning Curve

Susan E. Bates

Clin Cancer Res November 1 1999 5 (11) 3346-3348;
Editorials

Intrathecal Depot Cytarabine Therapy: A Welcome Addition to a Limited Armamentarium

W. Archie Bleyer

Clin Cancer Res November 1 1999 5 (11) 3349-3351;

Advances in Brief

Advances in Brief

Rapid Activation of MDR1 Gene Expression in Human Metastatic Sarcoma after in Vivo Exposure to Doxorubicin

Amir Abolhoda, Amy E. Wilson, Howard Ross, Peter V. Danenberg, Michael Burt and Kathleen W. Scotto

Clin Cancer Res November 1 1999 5 (11) 3352-3356;
Advances in Brief

Phase I Study of an Antisense Oligonucleotide to Protein Kinase C-α (ISIS 3521/CGP 64128A ) in Patients with Cancer,

Alan R. Yuen, Joanne Halsey, George A. Fisher, Jon T. Holmlund, Richard S. Geary, T. Jesse Kwoh, Andrew Dorr and Branimir I. Sikic

Clin Cancer Res November 1 1999 5 (11) 3357-3363;
Advances in Brief

Vascular Endothelial Growth Factor Levels and Induction of Permeability in Malignant Pleural Effusions

Brian K. Zebrowski, Seiji Yano, Wenbiao Liu, Raymond M. Shaheen, Daniel J. Hicklin, Joe B. Putnam Jr. and Lee M. Ellis

Clin Cancer Res November 1 1999 5 (11) 3364-3368;

Clinical Trials

Clinical Trials

A Phase I and Pharmacological Study of Protracted Infusions of Crisnatol Mesylate in Patients with Solid Malignancies

Miguel A. Villalona-Calero, Thierry Petit, John Kuhn, Patrick Cobb, Maura Kraynak, S. Gail Eckhardt, Ronald Drengler, Cecelia Simmons, Pedro Santabarbara, Daniel D. Von Hoff and Eric K. Rowinsky

Clin Cancer Res November 1 1999 5 (11) 3369-3378;
Clinical Trials

Coadministration of Oral Cyclosporin A Enables Oral Therapy with Paclitaxel

Jetske M. Meerum Terwogt, Mirte M. Malingré, Jos H. Beijnen, Wim W. ten Bokkel Huinink, Hilde Rosing, Franciska J. Koopman, Olaf van Tellingen, Martha Swart and Jan H. M. Schellens

Clin Cancer Res November 1 1999 5 (11) 3379-3384;
Clinical Trials

Phase I and Imaging Trial of a Monoclonal Antibody Directed against Gastrin-releasing Peptide in Patients with Lung Cancer

Arvind Chaudhry, Jorge A. Carrasquillo, Ingalill L. Avis, Noriyuki Shuke, James C. Reynolds, Richard Bartholomew, Steven M. Larson, Frank Cuttitta, Bruce E. Johnson and James L. Mulshine

Clin Cancer Res November 1 1999 5 (11) 3385-3393;
Clinical Trials

A Randomized Controlled Trial Comparing Intrathecal Sustained-release Cytarabine (DepoCyt) to Intrathecal Methotrexate in Patients with Neoplastic Meningitis from Solid Tumors

Michael J. Glantz, Kurt A. Jaeckle, Marc C. Chamberlain, Surasak Phuphanich, Lawrence Recht, Lode J. Swinnen, Bernard Maria, Susan LaFollette, G. Berry Schumann, Bernard F. Cole and Stephen B. Howell

Clin Cancer Res November 1 1999 5 (11) 3394-3402;
Clinical Trials

Classification and Regression Tree Analysis of 1000 Consecutive Patients with Unknown Primary Carcinoma

Kenneth R. Hess, Marie C. Abbruzzese, Renato Lenzi, Martin N. Raber and James L. Abbruzzese

Clin Cancer Res November 1 1999 5 (11) 3403-3410;
Clinical Trials

A Feasibility Study of Multiple Cycle Therapy with Melphalan, Thiotepa, and Paclitaxel followed by Mitoxantrone, Thiotepa, and Paclitaxel with Autologous Hematopoietic Cell Support for Metastatic Breast Cancer

Wendy W. Hu, Gwynn D. Long, Keith E. Stockerl-Goldstein, Laura J. Johnston, Nelson J. Chao, Robert S. Negrin and Karl G. Blume

Clin Cancer Res November 1 1999 5 (11) 3411-3418;
Clinical Trials

A Phase I Study of Paclitaxel, Etoposide, and Cisplatin in Extensive Stage Small Cell Lung Cancer

Karen Kelly, Zhaoxing Pan, Marie E. Wood, James Murphy and Paul A. Bunn Jr.

Clin Cancer Res November 1 1999 5 (11) 3419-3424;
Clinical Trials

A Predictive Model for Relapse in High-Risk Primary Breast Cancer Patients Treated with High-Dose Chemotherapy and Autologous Stem-Cell Transplant

Yago Nieto, Pablo J. Cagnoni, Elizabeth J. Shpall, Xuesheng Xu, James Murphy, James Vredenburgh, Nelson J. Chao, Scott I. Bearman and Roy B. Jones

Clin Cancer Res November 1 1999 5 (11) 3425-3431;
Clinical Trials

AIDS-related Kaposi’s Sarcoma: A Phase II Study of Liposomal Doxorubicin

Tony W. Cheung, Scot C. Remick, Nozar Azarnia, Jo Ann Proper, Jose R. Barrueco and Bruce J. Dezube

Clin Cancer Res November 1 1999 5 (11) 3432-3437;
Clinical Trials

α-Difluoromethylornithine as Treatment for Metastatic Breast Cancer Patients

Joyce A. O’Shaughnessy, Laurence M. Demers, Stephen E. Jones, James Arseneau, Pankaj Khandelwal, Timothy George, Robert Gersh, David Mauger and Andrea Manni

Clin Cancer Res November 1 1999 5 (11) 3438-3444;

Molecular Oncology, Markers, Clinical Correlates

Molecular Oncology, Markers, Clinical Correlates

Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype

Zhenfeng Duan, Aynn J. Feller, Richard T. Penson, Bruce. A. Chabner and Michael V. Seiden

Clin Cancer Res November 1 1999 5 (11) 3445-3453;
Molecular Oncology, Markers, Clinical Correlates

Prospective Assessment of Allelic Losses at 4p14–16 in Colorectal Cancer: Two Mutational Patterns and a Locus Associated with Poorer Survival

Rosa Arribas, Maria Ribas, Rosa-Ana Risques, Laia Masramon, Silvia Tórtola, Eugenio Marcuello, Gemma Aiza, Rosa Miró, Gabriel Capellà and Miguel A. Peinado

Clin Cancer Res November 1 1999 5 (11) 3454-3459;
Molecular Oncology, Markers, Clinical Correlates

Expression of Nuclear Receptor Interacting Proteins TIF-1, SUG-1, Receptor Interacting Protein 140, and Corepressor SMRT in Tamoxifen-resistant Breast Cancer

Christina M. W. Chan, Anne E. Lykkesfeldt, Malcolm G. Parker and Mitchell Dowsett

Clin Cancer Res November 1 1999 5 (11) 3460-3467;
Molecular Oncology, Markers, Clinical Correlates

Aberrant Fragile Histidine Triad Gene Transcripts in Primary Hepatocellular Carcinoma and Liver Cirrhosis

Laura Gramantieri, Pasquale Chieco, Maddalena Di Tomaso, Livia Masi, Fabio Piscaglia, Stefano Brillanti, Stefano Gaiani, Marco Valgimigli, Alighieri Mazziotti and Luigi Bolondi

Clin Cancer Res November 1 1999 5 (11) 3468-3475;
Molecular Oncology, Markers, Clinical Correlates

Allelic Loss in Esophageal Squamous Cell Carcinoma Patients with and without Family History of Upper Gastrointestinal Tract Cancer

Nan Hu, Mark J. Roth, Michael R. Emmert-Buck, Ze-Zhong Tang, Mihael Polymeropolous, Quan-Hong Wang, Alisa M. Goldstein, Xiao-You Han, Sanford M. Dawsey, Ti Ding, Carol Giffen and Philip R. Taylor

Clin Cancer Res November 1 1999 5 (11) 3476-3482;
Molecular Oncology, Markers, Clinical Correlates

Immunohistochemical Expression of Somatostatin Type 2A Receptor in Neuroendocrine Tumors

Noriko Kimura, Monika Pilichowska, Fumiko Date, Itaru Kimura and Marcus Schindler

Clin Cancer Res November 1 1999 5 (11) 3483-3487;
Molecular Oncology, Markers, Clinical Correlates

Human Ovarian Cancer, Cell Lines, and Primary Ascites Cells Express the Human Mullerian Inhibiting Substance (MIS) Type II Receptor, Bind, and Are Responsive to MIS

Peter T. Masiakos, David T. MacLaughlin, Shyamala Maheswaran, Jose Teixeira, Arlan F. Fuller Jr., Paresh C. Shah, David J. Kehas, Mary K. Kenneally, David M. Dombkowski, Thanh U. Ha, Frederic I. Preffer and Patricia K. Donahoe

Clin Cancer Res November 1 1999 5 (11) 3488-3499;
Molecular Oncology, Markers, Clinical Correlates

TP53 Accumulation Predicts Improved Survival in Patients Resistant to Systemic Cisplatin-based Chemotherapy forMuscle-invasive Bladder Cancer

K. N. Qureshi, T. R. L. Griffiths, M. C. Robinson, C. Marsh, J. T. Roberts, R. R. Hall, J. Lunec and D. E. Neal

Clin Cancer Res November 1 1999 5 (11) 3500-3507;
Molecular Oncology, Markers, Clinical Correlates

Apoptosis and Expression of Apoptosis Regulating Proteins bcl-2, mcl-1, bcl-X, and bax in Malignant Mesothelioma

Ylermi Soini, Vuokko Kinnula, Riitta Kaarteenaho-Wiik, Esko Kurttila, Kaija Linnainmaa and Paavo Pääkkö

Clin Cancer Res November 1 1999 5 (11) 3508-3515;
Molecular Oncology, Markers, Clinical Correlates

Different Patterns of Angiogenesis in Sarcomas and Carcinomas

James Tomlinson, Sanford H. Barsky, Scott Nelson, Samuel Singer, Behnaz Pezeshki, Maggie C. Lee, Frederick Eilber and Mai Nguyen

Clin Cancer Res November 1 1999 5 (11) 3516-3522;
Molecular Oncology, Markers, Clinical Correlates

Characterization of p53 Mutations in Colorectal Liver Metastases and Correlation with Clinical Parameters

Appolonia Tullo, Anna M. D’Erchia, Kazuo Honda, Ragai R. Mitry, Michael D. Kelly, Nagy A. Habib, Cecilia Saccone and Elisabetta Sbisà

Clin Cancer Res November 1 1999 5 (11) 3523-3528;
Molecular Oncology, Markers, Clinical Correlates

Circulating Soluble Fas Concentration in Breast Cancer Patients

Takayuki Ueno, Masakazu Toi and Takeshi Tominaga

Clin Cancer Res November 1 1999 5 (11) 3529-3533;
Molecular Oncology, Markers, Clinical Correlates

Evaluation of Soluble CD44v6 as a Potential Serum Marker for Head and Neck Squamous Cell Carcinoma

Nicole L. W. Van Hal, Guus A. M. S. Van Dongen, Corlinda B. M. Ten Brink, Karl-Heinz Heider, Irene Rech-Weichselbraun, Gordon B. Snow and Ruud H. Brakenhoff

Clin Cancer Res November 1 1999 5 (11) 3534-3541;
Molecular Oncology, Markers, Clinical Correlates

Importance of Nuclear Morphology in Breast Cancer Prognosis

William H. Wolberg, W. Nick Street and Olvi L. Mangasarian

Clin Cancer Res November 1 1999 5 (11) 3542-3548;
Molecular Oncology, Markers, Clinical Correlates

Genetically Fluorescent Melanoma Bone and Organ Metastasis Models

Meng Yang, Ping Jiang, Zili An, Eugene Baranov, Lingna Li, Satoshi Hasegawa, Maraya Al-Tuwaijri, Takashi Chishima, Hiroshi Shimada, A. R. Moossa and Robert M. Hoffman

Clin Cancer Res November 1 1999 5 (11) 3549-3559;
Molecular Oncology, Markers, Clinical Correlates

Five Novel Immunogenic Antigens in Meningioma: Cloning, Expression Analysis, and Chromosomal Mapping

Nicole Comtesse, Dirk Heckel, Alexander Rácz, Nicole Brass, Brenda Glass and Eckart Meese

Clin Cancer Res November 1 1999 5 (11) 3560-3568;
Molecular Oncology, Markers, Clinical Correlates

Deletion of Chromosome 1p and Loss of Expression of Alkaline Phosphatase Indicate Progression of Meningiomas

Patrick Müller, Wolfram Henn, Isolde Niedermayer, Ralf Ketter, Wolfgang Feiden, Wolf-Ingo Steudel, Klaus D. Zang and Heike Steilen-Gimbel

Clin Cancer Res November 1 1999 5 (11) 3569-3577;
Molecular Oncology, Markers, Clinical Correlates

Androgen Receptor Gene Alterations and Chromosomal Gains and Losses in Prostate Carcinomas Appearing During Finasteride Treatment for Benign Prostatic Hyperplasia

Pasi A. Koivisto, Johanna Schleutker, Heikki Helin, Conny Ehren-van Eekelen, Olli-Pekka Kallioniemi and Jan Trapman

Clin Cancer Res November 1 1999 5 (11) 3578-3582;

Experimental Therapeutics, Preclinical Pharmacology

Experimental Therapeutics, Preclinical Pharmacology

A Human Prolactin Antagonist, hPRL-G129R, Inhibits Breast Cancer Cell Proliferation through Induction of Apoptosis

Wen Y. Chen, Preveen Ramamoorthy, Nian-yi Chen, Robert Sticca and Thomas E. Wagner

Clin Cancer Res November 1 1999 5 (11) 3583-3593;
Experimental Therapeutics, Preclinical Pharmacology

Antitumor Activity of CEP-751 (KT-6587) on Human Neuroblastoma and Medulloblastoma Xenografts

Audrey E. Evans, Kristin D. Kisselbach, Darrell J. Yamashiro, Naohiko Ikegaki, Anna Marie Camoratto, Craig A. Dionne and Garrett M. Brodeur

Clin Cancer Res November 1 1999 5 (11) 3594-3602;
Experimental Therapeutics, Preclinical Pharmacology

BAY 12-9566, A Novel Inhibitor of Matrix Metalloproteinases with Antiangiogenic Activity

Carmen Gatto, Monica Rieppi, Patrizia Borsotti, Silvia Innocenti, Roberta Ceruti, Teresa Drudis, Eugenio Scanziani, Anna M. Casazza, Giulia Taraboletti and Raffaella Giavazzi

Clin Cancer Res November 1 1999 5 (11) 3603-3607;
Experimental Therapeutics, Preclinical Pharmacology

Radiotherapy and Dosimetry of ⁶⁴Cu-TETA-Tyr³-Octreotate in a Somatostatin Receptor-positive, Tumor-bearing Rat Model

Jason S. Lewis, Michael R. Lewis, P. Duffy Cutler, Ananth Srinivasan, Michelle A. Schmidt, Sally W. Schwarz, Margaret M. Morris, J. Philip Miller and Carolyn J. Anderson

Clin Cancer Res November 1 1999 5 (11) 3608-3616;
Experimental Therapeutics, Preclinical Pharmacology

Synergy of Topotecan in Combination with Vincristine for Treatment of Pediatric Solid Tumor Xenografts

Joyce Thompson, E. Olusegun George, Catherine A. Poquette, Pamela J. Cheshire, Lois B. Richmond, Siebold S. N. de Graaf, Margaret Ma, Clinton F. Stewart and Peter J. Houghton

Clin Cancer Res November 1 1999 5 (11) 3617-3631;
Experimental Therapeutics, Preclinical Pharmacology

Enhanced Antitumor Activity of Paclitaxel in Combination with the Anticarcinoma Immunoconjugate BR96-Doxorubicin

Pamela A. Trail, David Willner, Albert B. Bianchi, Arris J. Henderson, Mark D. TrailSmith, Emel Girit, Shirley Lasch, Ingegerd Hellström and Karl Erik Hellström

Clin Cancer Res November 1 1999 5 (11) 3632-3638;
Experimental Therapeutics, Preclinical Pharmacology

A Cell Type-specific and Gap Junction-independent Mechanism for the Herpes Simplex Virus-1 Thymidine Kinase Gene/Ganciclovir-mediated Bystander Effect

Frédéric Princen, Pierre Robe, Chantal Lechanteur, Marc Mesnil, Jean-Michel Rigo, Jacques Gielen, Marie-Paule Merville and Vincent Bours

Clin Cancer Res November 1 1999 5 (11) 3639-3644;
Experimental Therapeutics, Preclinical Pharmacology

Direct Comparison of Liposomal Doxorubicin with or without Polyethylene Glycol Coating in C-26 Tumor-bearing Mice

Ruey-Long Hong, Chang-Jen Huang, Yun-Long Tseng, Victor Fei Pang, Shui-Tsung Chen, Jun-Jen Liu and Fu-Hsiung Chang

Clin Cancer Res November 1 1999 5 (11) 3645-3652;
Experimental Therapeutics, Preclinical Pharmacology

The Outcome of Heregulin-induced Activation of Ovarian Cancer Cells Depends on the Relative Levels of HER-2 and HER-3 Expression

Fengji Xu, Yinhua Yu, Xiao-Feng Le, Cinda Boyer, Gordon B. Mills and Robert C. Bast Jr.

Clin Cancer Res November 1 1999 5 (11) 3653-3660;
Experimental Therapeutics, Preclinical Pharmacology

Expression of Bisecting GlcNAc in Pediatric Brain Tumors and Its Association with Tumor Cell Response to Vinblastine

Abdelhadi Rebbaa, Pauline M. Chou, Ivica Vucic, Bernard L. Mirkin, Tadanori Tomita and Eric G. Bremer

Clin Cancer Res November 1 1999 5 (11) 3661-3668;
Experimental Therapeutics, Preclinical Pharmacology

The Antiangiogenic Agent Linomide Inhibits the Growth Rate of von Hippel-Lindau Paraganglioma Xenografts to Mice

David J. Gross, Israel Reibstein, Lola Weiss, Shimon Slavin, Ilan Stein, Michal Neeman, Rinat Abramovitch and Laura E. Benjamin

Clin Cancer Res November 1 1999 5 (11) 3669-3675;
Experimental Therapeutics, Preclinical Pharmacology

Eradication of Human Medulloblastoma Tumor Xenografts with a Combination of O⁶-Benzyl-2′-deoxyguanosine and 1,3-Bis(2-chloroethyl)-1-nitrosourea

Demetrius M. Kokkinakis, Robert C. Moschel, Anthony E. Pegg and S. Clifford Schold

Clin Cancer Res November 1 1999 5 (11) 3676-3681;
Experimental Therapeutics, Preclinical Pharmacology

Pharmacokinetics of PK1 and Doxorubicin in Experimental Colon Tumor Models with Differing Responses to PK1

Paul M. Loadman, Mike C. Bibby, John A. Double, Waleed M. Al-Shakhaa and Ruth Duncan

Clin Cancer Res November 1 1999 5 (11) 3682-3688;
Experimental Therapeutics, Preclinical Pharmacology

Simplified Production of a Recombinant Human Angiostatin Derivative That Suppresses Intracerebral Glial Tumor Growth

Patricio I. Meneses, Lauren E. Abrey, Katherine A. Hajjar, S. Humayun Gultekin, Robert M. Duvoisin, Kenneth I. Berns and Myrna R. Rosenfeld

Clin Cancer Res November 1 1999 5 (11) 3689-3694;

Cancer Biology, Immunology, Cytokines

Cancer Biology, Immunology, Cytokines

Antagonistic Effect of NK4, a Novel Hepatocyte Growth Factor Variant, on in Vitro Angiogenesis of Human Vascular Endothelial Cells

Wen G. Jiang, Steve E. Hiscox, Christian Parr, Tracey A. Martin, Kunio Matsumoto, Toshikazu Nakamura and Robert E. Mansel

Clin Cancer Res November 1 1999 5 (11) 3695-3703;
Cancer Biology, Immunology, Cytokines

Lysophosphatidic Acid Induces Urokinase Secretion by Ovarian Cancer Cells

Terri B. Pustilnik, Veronica Estrella, Jon R. Wiener, Muling Mao, Astrid Eder, Mary-Anne V. Watt, Robert C. Bast Jr. and Gordon B. Mills

Clin Cancer Res November 1 1999 5 (11) 3704-3710;
Cancer Biology, Immunology, Cytokines

Constitutive and Inducible Interleukin 8 Expression by Hypoxia and Acidosis Renders Human Pancreatic Cancer Cells More Tumorigenic and Metastatic

Qian Shi, James L. Abbruzzese, Suyun Huang, Isaiah J. Fidler, Qinghua Xiong and Keping Xie

Clin Cancer Res November 1 1999 5 (11) 3711-3721;

Letters to the Editor

Letters to the Editor

Correspondence re: S. Shimoyama et al., Increased Serum Angiogenin Concentration in Colorectal Cancer Is Correlated with Cancer Progression. Clin. Cancer Res., 5: 1125–1130, 1999.

Sagrario Montero, Belén Lloveras, Hernán Cortés-Funes and Ramon Colomer

Clin Cancer Res November 1 1999 5 (11) 3722-3723;
Letters to the Editor

Correspondence re: G. Tallini et al., RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotype. Clin. Cancer Res., 4:287–294, 1998.

Paula Soares and Manuel Sobrinho-Simões

Clin Cancer Res November 1 1999 5 (11) 3724-3725;

Main menu

User menu

Search

Table of Contents

Editorials

Advances in Brief

Clinical Trials

Molecular Oncology, Markers, Clinical Correlates

Experimental Therapeutics, Preclinical Pharmacology

Cancer Biology, Immunology, Cytokines

Letters to the Editor

Jump to

Articles

Info for

About Clinical Cancer Research